Virginia is currently home to 1860 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Richmond, Charlottesville, Norfolk and Fairfax. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Efficacy and Safety of Plecanatide in Children 6 to <18 Years of Age With Irritable Bowel Syndrome With Constipation (IBS-C)
NCT03596905
Recruiting
This study of the efficacy and safety of Plecanatide in children 6 to <18 Years of Age with Irritable Bowel Syndrome with Constipation (IBS-C)
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
02/06/2023
Locations: Synergy Research Site, Newport News, Virginia
Conditions: Irritable Bowel Syndrome With Constipation
Register for Updates
A Performance Evaluation Study of Arquer's MCM5 Elisa Test (ADXBLADDER) to Aid in the Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer
NCT05508568
Recruiting
The objective of this prospective, multi-centre study is to evaluate the performance of ADXBLADDER, a urine MCM5 ELISA test, as an aid in the detection of bladder cancer recurrence. Patients undergoing cystoscopic surveillance in non-muscle invasive bladder cancer (NMIBC) follow-up will be recruited and asked to provide a urine sample to be tested with ADXBLADDER. To assess the diagnostic accuracy of the test, the MCM5 results will be compared with the gold standard cystoscopy and pathology of r... Read More
Gender:
All
Ages:
22 years and above
Trial Updated:
01/30/2023
Locations: Virginia Urology Center, Richmond, Virginia
Conditions: Bladder Cancer
Register for Updates
Collection of Samples USOPTIVAL Study
NCT04792684
Recruiting
A prospective multi-center observational study. The study will enroll eligible subjects from the United States to optimize the biomarker panel and evaluate the performance of a cfDNA marker panel selected by the Sponsor for CRC and advanced adenoma detection.
Gender:
All
Ages:
Between 45 years and 84 years
Trial Updated:
01/26/2023
Locations: Gastroenterology Consultants of SW Virginia, Roanoke, Virginia
Conditions: Colorectal Cancer (CRC), Advanced Adenomas (AA)
Register for Updates
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
NCT05002127
Recruiting
A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/23/2023
Locations: NEXT Virginia, Fairfax, Virginia
Conditions: Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
Register for Updates
Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC
NCT04295811
Recruiting
The study will assess the performance of the combined system, i.e., the use of the EsoGuard assay (lab developed test) on cells collected using the EsoCheck (501k cleared device) to detect Barrett's Esophagus (BE), with or without dysplasia, and esophageal adenocarcinoma (EAC) as compared to Esophagogastroduodenoscopy (EGD) plus biopsies in both confirmed cases of BE/EAC and in controls (subjects without a prior diagnosis but undergoing screening for BE/EAC)
Gender:
Male
Ages:
50 years and above
Trial Updated:
01/23/2023
Locations: Lucid Investigative Site, Richmond, Virginia
Conditions: Barrett Esophagus, Esophageal Adenocarcinoma, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia
Register for Updates
Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)
NCT04502316
Recruiting
The purpose of this registry is to develop valid scientific evidence of the safety and benefit of Barostim Therapy in the commercial setting in patients with heart failure with reduced ejection fraction (HFrEF) that were recently implanted with the Barostim System.
Gender:
All
Ages:
All
Trial Updated:
01/21/2023
Locations: Carient Heart & Vascular, Manassas, Virginia
Conditions: Heart Failure
Register for Updates
Vaginal Cuff Brachytherapy Fractionation Study
NCT03785288
Recruiting
The purpose of this study is to see the effects of two different standard of care treatments of endometrial cancer on sexual dysfunction. This study will compare two standard of care treatments: HDR (high dose radiation) vaginal brachytherapy 3 fractions of 7 Gy to HDR vaginal brachytherapy 6 fractions of 4Gy for early stage endometrial cancer.
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/19/2023
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Endometrial Cancer
Register for Updates
Gut Microbiome and Blood Indices in Patients With AD and Their Spousal Caregivers
NCT05601856
Recruiting
Spousal caregivers of Alzheimer's Dementia (AD) patients have an elevated risk of developing AD in the future. Past studies have shown the presence of serum indicators correlated with gut biome dysfunction in AD patients. We hypothesize that the same gut biome dysfunction may be present in spousal caregivers of AD patients.
Gender:
All
Ages:
Between 65 years and 90 years
Trial Updated:
01/18/2023
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Alzheimer Disease, Gut Biome
Register for Updates
Her2-BATS and Pembrolizumab in Metastatic Breast Cancer
NCT03272334
Recruiting
This proposal uses HER2Bi armed activated T-cells (HER2 BATs) to target breast cancer in combination with pembrolizumab (PBZ) in women with metastatic breast cancer (MBC). Phase I will determine a safe dose of the combination of PBZ and HER2 BATs in 3 to 18 patients. In the phase II portion, an additional 12 patients will be treated at the selected dose to further evaluate the safety and preliminary efficacy. Study treatment includes a combination of 8 infusions of BATs using a previously estab... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/18/2023
Locations: Ashley Donihee, Charlottesville, Virginia
Conditions: Metastatic Breast Cancer
Register for Updates
Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors
NCT04900519
Recruiting
This is a first-in-human, phase 1, open-label, dose-escalation study of STI-6643 administered by intravenous infusion in subjects with a relapsed/refractory advanced solid tumor.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/12/2023
Locations: Virginia Cancer Specialists, Fairfax, Virginia
Conditions: Solid Tumor, Relapsed Solid Neoplasm, Refractory Tumor
Register for Updates
Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL
NCT03240211
Recruiting
This is an international, multicenter, multi-arm, phase Ib, model-based dose-escalation study. The primary objectives of the study in each arm is to determine the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), dose limiting toxicities (DLTs) and to evaluate the clinical efficacy at the MTD of various combinations of pembrolizumab, pralatrexate and decitabine.
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
01/05/2023
Locations: University of Virginia, Charlottesville, Virginia
Conditions: PTCL, CTCL
Register for Updates
Identification of Patients With a High Probability of Meeting Eligibility Criteria for an Alzheimer's Disease Clinical Trial (APHELEIA)
NCT05364307
Recruiting
Apheleia-001 is a prescreener that aims to identify and characterize participants with reported cognitive impairment using demographic information, clinical history, brief cognitive assessments, and blood-based biomarkers to distinguish appropriate participants for referral to a therapeutic AD clinical trial.
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
12/28/2022
Locations: Re:Cognition Health, Fairfax, Virginia
Conditions: Alzheimer Disease, Mild Cognitive Impairment, Memory Loss, Memory Disorders, Memory Impairment
Register for Updates